As previously reported, on December 12, 2017, the Ontario Legislature passed the Strengthening Quality and Accountability for Patients Act, 2017, which enacts or amends 10 statutes including the Health Sector Payment Transparency Act, 2017 (Transparency Act). When in force, the Transparency Act will require disclosure of financial relationships between pharmaceutical or medical device manufacturers (among other “payors”) and health care professionals (among other “recipients”). On February 21, 2018, the Ontario Ministry of Health and Long-Term Care published for consultation proposed regulations under the Transparency Act. The proposed regulations specify: what constitutes a “transfer of value” that must be reported; who qualifies as an “intermediary” or a “recipient” of a “transfer of value”; additional categories of “payors”; what thresholds and exemptions exist to the reporting requirements; the manner and frequency of reporting; and the process for correcting posted information. The consultation period ends April 6, 2018.
Related Publications & Articles
-
Health Canada finalizes biosimilar guidance: comparative clinical efficacy studies not typically required
In Canada, biosimilar products are approved by way of a new drug submission, following Health Canada guidance first released in 2010 and significantly revised in 2016.Read More -
2026 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2026, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top storiesRead More -
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More
